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SUMMARY 
 
Introduction: Bone scintigraphy is used extensively in evaluating metastatic disease. 
There are currently no clear recommendations for the use of SPECT/CT in metastatic 
bone disease. Existing procedural guidelines from the Society of Nuclear Medicine 
(SNM) for SPECT/CT do not provide specific indications for use of SPECT/CT in bone 
scintigraphy, and there are currently no other guidelines for the use of SPECT/CT in 
bone scintigraphy that the author is aware of. The aim of this study was to investigate 
the additional value of SPECT/CT, and to identify the clinical indications for which 
SPECT/CT is most useful in patients with suspected bone metastases.  
 
Subjects and Methods: Forty-two patients with equivocal lesions on planar 
scintigraphy were prospectively recruited and planar imaging, SPECT, and SPECT/CT 
done on all patients. On reading of SPECT and then SPECT/CT, patients and individual 
lesions were classified as malignant, benign or equivocal. Radiological studies and 
available clinical information were also used during reading of scans. Review of clinical 
information, radiological studies and/or follow-up bone scans were used as gold 
standard. The results of the SPECT and SPECT/CT were compared in terms of 
proportion of equivocal findings and accuracy. 
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Results: Forty-two patients with 189 skeletal lesions were examined. There was a 
diverse variety of primary tumours, although the majority had breast (n=22) or prostate 
cancer (n=8). Overall, SPECT/CT resulted in a significant reduction in the proportion of 
equivocal findings on both a patient-wise (p=0.0015) and lesion-wise basis (p<0.0001). 
The overall accuracy of SPECT/CT was significantly higher than that of SPECT on both 
a patient-wise (p=0.0026) and lesion-wise basis (p<0.0001). Generally SPECT/CT 
decreased the proportion of equivocal findings and increased the accuracy independent 
of the presence of bone pain, type of primary tumour, or skeletal region involved. 
SPECT/CT did not significantly improve the diagnostic confidence of readers in 
equivocal lumbar lesions although accuracy was significantly improved in this region. 
 
Conclusion: SPECT/CT performs significantly better than SPECT alone for the 
interpretation of equivocal planar lesions. There is no evidence that the benefit of 
SPECT/CT is dependent on the type of primary tumour or the presence of bone pain. 
Where resources are limited, SPECT/CT is indicated only in those patients in whom 
correct classification of the lesions in question is expected to alter the patient’s 
management. SPECT/CT images should be interpreted with the aid of a diagnostic 
radiologist or nuclear medicine physicians should acquire sufficient experience in 
Computed Tomographic image interpretation in order to optimise diagnostic benefit from 
SPECT/CT. 
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OPSOMMING 
 
Inleiding: Beenflikkergrafie word wyd vir die evaluering van metastatiese siekte 
gebruik. Daar bestaan tans geen duidelike aanbevelings vir die gebruik van 
Enkelfotonemissie rekenaartomografie gekombineer met rekenaartomografie 
(EFERT/RT, Engels SPECT/CT) in metastatiese beensiekte nie. Bestaande riglyne van 
die Amerikaanse Society of Nuclear Medicine (SNM) vir EFERT/RT gee nie spesifieke 
indikasies vir die gebruik van EFERT/RT in beenflikkergrafie nie, en daar is tans geen 
ander riglyne waarvan die outeur bewus is nie. Die doel van hierdie studie was om die 
bykomende waarde van EFERT/RT te ondersoek, en om dié kliniese indikasies waar 
EFERT/RT in pasiënte met vermoedelike beenmetastases mees nuttig sal wees, te 
identifiseer. 
Pasiënte en Metodes: Twee en veertig pasiënte met twyfelagtige letsels op planare 
skeletflikkergrafie is prospektief geselekteer en planare beelding, EFERT en EFERT/RT 
is op alle pasiënte gedoen.  Tydens beoordeling van EFERT en daarna EFERT/RT 
beelde is pasiënte en individuele letsels as maligne, benigne of twyfelagtig 
geklassifiseer. Radiologiese studies en beskikbare kliniese inligting is ook tydens 
interpretasie van flikkergramme gebruik. Kliniese inligting, radiologiese studies en/of 
opvolg beenflikkergramme is as goue standaard gebruik. Die resultate van EFERT en 
EFERT/RT is ten opsigte van die aantal twyfelagtige bevindings en akkuraatheid 
vergelyk.   
Resultate: Twee en veertig pasiënte met 189 skeletale letsels is ondersoek. Daar was 
‘n verskeidenheid van primêre tumore, maar die meerderheid van pasiënte het bors- 
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(n=22) of prostaatkanker (n=8) gehad. Die gebruik van EFERT/RT het gelei tot ‘n 
betekenisvolle afname in die aantal twyfelagtige bevindings, beide op ‘n pasiënt- en ‘n 
letselbasis (p=0.0015 en p<0.0001 onderskeidelik). Die algehele akkuraatheid van 
EFERT/RT was betekenisvol hoër as die van EFERT alleen, beide op pasiënt- en op 
letselbasis (p=0.0026 en p<0.0001 onderskeidelik). Oor die algemeen het EFERT/RT 
die aantal twyfelagtige letsels verminder en die akkuraatheid verhoog,  ongeag die 
teenwoordigheid van beenpyn, die tipe primêre tumor of die area van die skelet wat 
betrokke was.  In twyfelagtige lumbale letsels het EFERT/RT nie die diagnostiese 
vertroue van beoordelaars van flikkergramme verhoog nie, alhoewel die akkuraatheid 
vir hierdie gebied wel betekenisvol toegeneem het.   
 
Gevolgtrekking: EFERT/RT vaar betekenisvol beter as EFERT in die beoordeling van 
twyfelagtige letsels op planare beenflikkergramme. Daar is geen bewys dat die voordeel 
van EFERT/RT afhanklik is van die tipe primêre tumor of die teenwoordigheid van 
beenpyn nie. Waar hulpbronne beperk is, is EFERT/RT slegs aangedui in dié pasiënte 
waar verwag word dat korrekte klassifikasie van die betrokke letsel behandeling sal 
beïnvloed. EFERT/RT beelde behoort met die hulp van ‘n diagnostiese radioloog 
beoordeel te word, of kerngeneeskundiges moet genoegsame ondervinding in die 
interpretasie van rekenaartomografiebeelde hê om die diagnostiese voordeel van 
EFERT/RT optimaal te kan benut.   
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CHAPTER 1 
 
INTRODUCTION 
 
Bone scintigraphy is one of the most commonly performed nuclear medicine procedures 
in most nuclear medicine departments, with an average of 24 bone scans performed per 
week at Tygerberg Hospital. Indications for bone scans include the detection of skeletal 
metastatic deposits, and the evaluation of other bone and joint diseases. Data obtained 
from a recent study at Tygerberg Hospital showed that 75% of patients undergoing a 
bone scan were investigated for metastasis, and of these, 51% of patients had breast 
cancer.1 Fifty eight percent of patients were positive for skeletal involvement, while the 
results of bone scans in 11% of patients investigated for skeletal metastasis were 
equivocal with no definitive diagnosis. 
 
The skeleton is the third most common localisation site of malignant tumours after the 
lungs and liver, with solid tumours exhibiting a relatively high rate of metastasis in the 
skeletal system depending on the primary tumour.2 Bone metastases are the most 
common bone tumour, occurring in 30-70% of all cancer patients, with breast cancer 
being the leading cause in women and prostate cancer in men, followed by lung 
cancer.3 About 75% of patients with malignancy and pain have been shown to have 
abnormal bone scan findings, and 25-45% of asymptomatic patients with malignancy 
were shown to have scintigraphic evidence of bone metastasis.4 
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With metastases constituting the major cause of treatment failure in cancer patients, the 
early detection of bone and bone marrow metastases is important as it allows for a rapid 
initiation of appropriate therapy and a reduction in morbidity. The initial localisation of 
metastases in the bone of patients with solid tumours has a relatively good prognosis in 
comparison with visceral metastasisation.5 Visceral metastases are more likely to be 
fatal, with long-term survival falling from 90 to around 5%.6 In contrast, patients with 
only metastases to bone can survive up to 10 years or more.7,8,9,10 
 
Bone scintigraphy has been shown to be very sensitive in detecting skeletal metastatic 
lesions.11 Its main purpose is to identify bone metastases as early as possible, to 
determine the full extent of the disease, to predict complications of malignant bone 
involvement (pathologic fractures, spinal cord compression etc), to monitor response to 
therapy, and sometimes to guide biopsies.12 
 
More than 90% of metastatic bone lesions occur in the axial skeleton and the spine is 
the most common site of skeletal metastases (39%).13-14 Therefore, the optimal 
interpretation of skeletal lesions is particularly important in this region of the skeleton. 
With a large proportion of skeletal metastasis being found in the vertebral column, it is 
very important that benign lesions be distinguished from those that are malignant. Bone 
metastases indicate a poorer prognosis, and patient management plans depend on 
whether or not skeletal metastases are present. They may also lead to various 
complications, including fractures, hypercalcaemia, and bone pain, and a reduced 
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performance status and quality of life.15 Isolated lesions in the rest of the skeleton are 
often also equivocal with metastasis being difficult to distinguish from other causes of 
osteoblastic activity such as trauma, arthritis etc. 
 
There is growing evidence that the fusion of images between separate modalities can 
be of considerable help in guiding patient care in many circumstances.16 Computed 
Tomography (CT) is commonly used in side-by-side visual comparison with SPECT 
slices. In the 1980s images were fused with software that used external or internal 
markers identifiable on both anatomical (CT) and functional (SPECT) studies.17 Success 
of this co-registration method was seen mainly with studies of the brain because of its 
rigid structure. Corresponding techniques for other regions of the body did not achieve 
the same widespread clinical use. Image co-registration in the chest or abdomen is 
more difficult because most alignment algorithms rely on the presence of mutual 
information between the two sets of images and in the abdomen the functional image 
may contain little correlative anatomical information. A confounding issue is the fact that 
the SPECT and CT data is usually acquired on different days, on different systems, and 
using unrelated protocols by different operators. The chest and abdomen are not rigid 
structures and differences in patient positioning, movement of internal organs, and 
respiratory motion make it difficult to align anatomical and functional images obtained 
during separate acquisition sessions.  
 
In recent years the integration of anatomical imaging techniques and SPECT has 
undergone significant growth. The first commercial SPECT/CT system was the GE 
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HawkeyeTM (GE Health Care, Haifa Israel) which was developed in 1999.18 This system 
integrates a variable-angle gamma camera with a low-dose single-slice CT scanner 
within the same gantry. The CT component in this system is used mainly for attenuation 
correction and localisation, rather than diagnostic radiology. Its design offers 
advantages over side-by-side visual analysis and software co-registration as this 
equipment enables the patient to be imaged on the same bed, in the same position with 
a minimal delay between SPECT and CT image acquisition. 
 
SPECT/CT hybrid scanners have been reported to show improved diagnostic accuracy 
over SPECT alone in conditions such as lymphoma,19 infection,20 bone disease,21 
neuroendocrine tumours,22-23 parathyroid adenomas,24-25 thyroid cancer,26-27 adrenal 
tumours,28 cavernous haemangiomas,29-30 and lymphoscintigraphy,31-32 Its use in the 
evaluation of possible skeletal metastases is still evolving. It is clear that fused images 
are not required for all imaging studies, hence in order to optimise the utilisation of this 
new technology, there is a need to identify the clinical indications for which image fusion 
is most useful in influencing patient care and outcome.16 There are currently no clear 
recommendations for the use of SPECT/CT for these patients. Existing procedure 
guidelines from the Society for Nuclear Medicine (SNM) for SPECT/CT do not provide 
specific indications for use of SPECT/CT in bone scintigraphy. There are currently no 
other guidelines for the use of SPECT/CT in bone scintigraphy that the author is aware 
of. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
PATHOPHYSIOLOGY OF SKELETAL METASTASES 
 
A metastatic deposit can be defined as a growth of malignant cells separate from the 
primary tumour which arises from detached fragments of the primary tumour. The 
histological features of the metastatic cells are similar to those of the primary tumour. 
 
The development of skeletal metastases involves two main stages33: (1) penetration of 
cells from the primary tumour into the blood vessels or lymphatic system, release of 
tumour emboli into the circulation, arrest of emboli in small vascular channels, and 
infiltration into the adjacent tissue; and (2) growth into a metastatic tumour. Metastatic 
cell deposits are in turn susceptible to spread, resulting in further metastases. 
 
The dissemination, growth and survival of malignant cells are determined by both host 
and tumour tissue factors.34 Pathways for the spread of tumour cells include 
haematogenous, lymphatic, direct infiltration and cerebrospinal fluid. Invasiveness is a 
fundamental and distinguishing characteristic of malignant tumour cells, enabling them 
to penetrate into lymphatics, blood vessels, and surrounding tissues.33 Vascular 
penetration plays a more important role than lymphatic infiltration in the development of 
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skeletal metastases. Prostate, kidney, breast, lung and thyroid cancers account for 80% 
of skeletal metastases and about 20-50% of solitary spinal lesions are due to metastatic 
spread.3,35 A large proportion (about 90%) of metastatic deposits in bone are located in 
regions containing red marrow due to the higher vascularity of red marrow compared to 
yellow marrow or bone cortex,11 and due to the fact that the majority of tumours 
metastasising to bone spread by the haematogenous route. Consequently, metastases 
do not affect all the bones with the same pattern and frequency, but generally prefer the 
spine and pelvis. Evidence of venous connection between the peri-prostatic and lumbar 
plexuses was first described by Batson et al in 1940.36 The authors evidenced the 
existence of a network of longitudinal, valveless vessels, running parallel to the 
vertebral column and forming countless anastomoses to the sinusoidal structure of the 
vertebral marrow. As metastases enlarge within marrow, surrounding bone undergoes 
osteoclastic and osteoblastic reactive changes. Skeletal metastases usually begin in the 
medulla of bone and ultimately lead to cortical damage.37 
 
There is a limited fashion in which bone can react to the presence of metastatic 
deposits. There can be either bone resorption (lytic bone metastases), or bone 
formation (sclerotic/blastic metastases); however, the most common pattern of bone 
response is a mixture of formation and resorption. A lytic or blastic response may 
predominate in any given patient.38 Thyroid and renal carcinomas frequently produce 
lytic lesions, and prostatic carcinoma is typically associated with blastic metastases. 
Lung and breast cancer often produce mixed lytic and blastic deposits. 
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Based on the balance between the osteoclastic (lytic) and osteoblastic (sclerotic) 
processes, the radiographic appearance of bone metastases may be lytic, sclerotic or 
mixed. The difference, however, in the basic pathologic processes is minor.39 This is 
because a simultaneous process of bone formation and destruction occurs in the 
majority of metastases. Where bone formation predominates, the lesion appears 
sclerotic, and where bone destruction predominates the lesion appears lytic. Mixed 
lesions demonstrate a combination of both bone formation and bone destruction. 
  
New bone formation in a metastatic lesion appears to occur by two main mechanisms, 
namely stromal and reactive bone formation, both mediated by osteoblasts.40 Stromal 
bone formation consists of the development of intramembranous ossification within 
fibrous stroma that develops around the tumour. Reactive bone formation occurs as a 
response to bone destruction and plays a more important role than stromal bone 
formation in bone metastases. The new bone may be similar to the callus that develops 
in fracture healing and is laid down in response to stress on the weakened bone. 
Reactive bone formation is seen in most metastases with the exception of highly 
anaplastic rapidly growing tumours, myeloma, lymphoma, and leukaemia, in which 
reactive bone formation is rare. Sclerosis may also be a sign of repair after treatment of 
bone malignancy. 
 
At least two main mechanisms are attributed to bone destruction (osteolysis) that occurs 
in skeletal metastases, the more important being osteoclast-mediated destruction.28 
Osteoclast proliferation occurs in most skeletal metastases in the vicinity of the tumour 
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and is believed to be mediated by osteoclast stimulating factors secreted by the tumour. 
The tumour continues to grow and destroy bone until a late stage when multinucleate 
osteoclasts disappear and there is no new bone formation. At this stage the tumour 
cells are directly responsible for the bone destruction possibly due to their secretion of 
lytic enzymes. Non-malignant macrophages are also believed to play a role. 
 
INVESTIGATIONS FOR SKELETAL METASTASES 
 
A patient with a malignant bone tumour, whether primary or metastatic, may seek 
treatment for various reasons which include pain in the lesion, pathological fracture, or 
an incidental finding on imaging. Back pain occurs frequently and is the most common 
symptom to bring a patient to an orthopaedic clinic as the spine is the most common 
site of metastatic involvement.41 It is important to differentiate pain secondary to 
malignant disease from that due to a benign cause. Many patients with bone 
metastases are asymptomatic and metastases are detected incidentally on routine 
screening or when a cause for rising tumour marker is looked for. For patients with 
known or presumed skeletal metastases, the clinical circumstances will determine the 
manner in which various imaging modalities will be used.42,43,44 
 
There are various imaging modalities available for the investigation of skeletal 
metastases which include conventional radiography, bone scintigraphy, Computed 
Tomography (CT), Magnetic Resonance Imaging (MRI), and Positron Emission 
Tomography (PET). According to the American college of Radiology, the first line of 
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imaging should be radiography as it is relatively inexpensive and the differential 
diagnoses of most primary tumours can be made based on radiographic features.45 This 
is probably true if there is bone pain and in cases of primary bone tumours. In the case 
of whole body staging for asymptomatic cases, bone scintigraphy is the logical first line 
imaging modality as it is more sensitive and subjects the patient to less radiation. Non-
imaging investigations include biopsy (which may be done under image guidance) and 
biochemistry. Each modality of investigating bone metastases has its inherent 
advantages and limitations. 
 
SKELETAL SCINTIGRAPHY 
 
INDICATIONS 
 
Technetium-99m Methylene Diphosphonate (99mTc-MDP) skeletal scintigraphy remains 
the most common method for the whole body assessment of bone metastases.38 It is 
the initial staging modality in cancer patients who are at high risk for skeletal 
metastases. Referral for bone scintigraphy may also be made in order to evaluate the 
response of known bone metastases to therapy, for routine follow-up to monitor 
progress of disease, or to determine the cause of bone pain. It provides a sensitive, 
cost-effective, rapid means of identifying skeletal metastases. 
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Schirrmeister and co-workers published data indicating that 14% to 22% of patients with 
non-small-cell lung carcinoma would have undergone futile thoracotomy or neoadjuvant 
chemotherapy if asymptomatic patients were denied a bone scan.46 18F-PET-CT has 
been shown to have significant impact in this regard as its sensitivity is greater than that 
of bone scintigraphy in the diagnosis of bone metastases from lung cancer.83 The cost-
effectiveness of bone scintigraphy was also described in a cohort of patients with 
varying types of primary tumours being investigated for skeletal metastases.47 
 
  
RADIOPHARMACEUTICALS 
 
The radiopharmaceuticals commonly used for bone scintigraphy are the 99mTc-labelled 
Diphosphonate compounds, Hydroxy-methylene Diphosphonate (HDP or HMDP), and 
Methylene Diphosphonate (MDP) with the general consensus being that they exhibit 
similar behaviour in vivo.48 Other radiopharmaceuticals such as 99mTc-labelled 
pyrophosphate have been used for bone scintigraphy but have largely been replaced by 
the Diphosphonates which are more stable in vivo. This stability is explained by the fact 
that the P-O-P bond in phosphates is easily broken down by phosphatase enzymes 
whereas the P-C-P bond of diphosphonates is not.49 
 
 
The factors that influence the uptake of diphosphonates by bone are the regional bone 
blood flow, the rate of bone formation governed by osteoblastic activity, and the 
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extraction efficiency. The higher the rate of blood flow and bone formation, the greater 
the uptake of tracer by bone. There are two hypotheses on the bone uptake mechanism 
of phosphonate compounds, namely hydroxyapatite uptake and collagen uptake.48 It 
has been suggested that in the hydroxyapatite uptake theory that hydroxyapatite crystal 
removes the phosphonate component from 99mTc-phosphonate complexes, setting free 
reduced technetium-99m to bind independently to hydroxyapatite at another binding 
site. Hydroxyapatite constitutes the inorganic matrix of bone and is primarily composed 
of calcium phosphate, and to some extent calcium carbonate and calcium hydroxide. 
The collagen uptake theory suggests that 99mTc-phosphonate complexes localise in 
both inorganic and organic matrices of bone, the latter uptake depending on the amount 
of immature collagen present.48 
 
After intravenous injection, about 50% of the activity accumulates in bone. Maximum 
bone activity is reached at one hour after injection and remains constant for up to 72 
hours.50 About 3% of injected activity remains in the blood stream three hours after 
injection. More than 30% of unbound 99mTc-MDP is cleared by glomerular filtration in 
one hour in patients with normal renal function, with about 60% being cleared in six 
hours. 
 
Metastatic deposits which exhibit an osteoblastic response will be visualised as an area 
of high count density or a “hot spot” on the bone scan, while those with a purely 
osteolytic reaction may not be detectable unless they are large enough to be seen as 
areas of reduced count density or a “cold spot”. Some tumours are so highly aggressive 
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that they do not allow an osteoblastic response to take place, leading to such a 
scintigraphic appearance.42 
 
SCINTIGRAPHIC IMAGE INTERPRETATION 
 
Despite its high sensitivity for detecting skeletal metastases, skeletal scintigraphy has 
low specificity and should not be interpreted in isolation. Rather, scintigraphic images 
should be read together with the clinical history and any available radiological modalities 
that may have been carried out in order to reduce the incidence of false-positives.37 
After an abnormality has been detected by a bone scan, selected radiographs should be 
performed to permit evaluation of scan-positive areas and should be interpreted in 
conjunction with the scan.51 Detection of a solitary or few bone lesions on bone scan 
often indicates the need for further assessment of the lesions, most common correlation 
being with plain radiographs or Computed Tomography (CT).52,53 In some cases, 
however, disseminated metastases often show a pattern that is typical of skeletal 
metastatic disease and hence specific. Proliferative changes in the axial skeleton in 
association with spondylosis or osteoarthritis and articular erosions from inflammatory 
arthritis may produce confusing patterns on scintigraphy. Thus, when correlative 
radiographs are not already available, they should be performed for those areas that 
have equivocal or suspicious scintigraphic findings.54 In most cases, however, 
degenerative disease can be identified on SPECT and even planar scintigraphy in other 
joints e.g. knees, ankles, shoulders. 
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Bone scintigraphy may be done in the form of planar images in which anterior and 
posterior views are acquired with the gamma camera. Abnormal areas on the skeleton 
may be seen as areas of either increased or decreased tracer uptake. It is important, 
however, to note that there are normal areas within the skeleton which may show 
relatively high tracer uptake. These include the base of the skull, the costochondral 
junctions, external occipital protuberances, paranasal sinuses, inferior tips of the 
scapulae, spinous processes of vertebrae, sternum, sternoclavicular joints, 
sternomanubrial joints, sacroiliac joints and unfused epiphyses in growing children and 
adolescents.42 Some non-osseous structures may also be visualised on the bone scan 
such as the genitourinary system (due to excretion of radiopharmaceutical), trauma and 
inflammation, and the injection site. Soft tissue calcifications may also be seen on a 
bone scan. 
 
There are various scintigraphic features that suggest that skeletal abnormalities are 
possibly metastatic. These include asymmetry, multiple random distribution, extreme 
variation in intensity, and occurrence of the abnormality being primarily in the skeleton.55 
If metastases are widespread and diffuse, they may produce what is described as a 
“super scan”, in which there is high skeletal uptake of tracer with absent or very minimal 
renal excretion or uptake.46  
 
In the interpretation of planar scintigrams, it is important to know the pathophysiology 
and specific characteristics of the primary tumour in order to determine the significance 
of any scan abnormalities as accurately as possible. The scan findings must be 
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correlated with the patient’s clinical history, physical examination findings, previous scan 
results, and the results of other imaging modalities that may have been performed. 
 
When it is not possible to differentiate between benign and malignant lesions on planar 
scintigraphy alone, single photon emission computed tomography (SPECT) may be 
performed in order to improve the diagnostic accuracy for detecting malignant bone 
involvement. This is especially applicable to lesions in the spine where the complex 
structure of the vertebrae makes it difficult to localise an abnormality accurately. SPECT 
also allows for a direct comparison with other tomographic-based imaging techniques 
such as Computed Tomography and Magnetic Resonance Imaging. Other indications 
for performing SPECT include back pain in a patient with known malignancy, and 
suspicious findings on other imaging studies, despite a normal planar bone scan. 
 
The overall sensitivity of bone SPECT (Single Photon Emission Computed 
Tomography) is between 87% and 92% with a specificity of nearly 91%.3 It has been 
found to be superior to planar scintigraphy in the detection and localisation of lesions in 
the axial skeleton.56 SPECT detects 20%-50% more lesions in the spine than planar 
scintigraphy.57 The pattern of uptake in the vertebrae allows malignant disease to be 
distinguished from more benign pathology with SPECT imaging. It has been 
demonstrated that increased uptake in the body of the vertebrae on SPECT imaging 
has a positive predictive value of 83-95% for malignancy.58,59 Uptake in the anterolateral 
and posterolateral aspects of the vertebrae (including facet joints) sparing the 
substance of the vertebral body was shown generally to be due to benign disease. 
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Some lesions, however, will remain indistinguishable on SPECT and may require further 
workup in order to elucidate their significance. 
 
Bone scintigraphy is commonly used as a means of follow-up in patients receiving 
therapy for previously diagnosed bone metastases. Post-therapy, healing may be 
indicated by a decrease in the intensity of tracer uptake or disappearance of lesions that 
had been detected on a baseline study. Bone repair is commonly associated with 
transiently increased osteoblastic activity, and a bone scan may not be able to 
accurately differentiate between ongoing disease and the “flare phenomenon”.60,61 In 
addition, lytic lesions previously overlooked pre-therapy may later present as “new” sites 
of increased uptake and may be misinterpreted as indicating disease progression. Flare 
phenomenon usually occurs during the first 3 months after initiation of therapy with a 
gradual decrease in intensity of uptake after 6 months. 
 
STRENGTHS AND LIMITATIONS OF SKELETAL 
SCINTIGRAPHY 
 
Skeletal scintigraphy is highly sensitive for the detection of most bone metastases with 
the ability to image the whole body at relatively low cost and low radiation dose.62 It may 
be used as a tool to guide biopsy for tissue diagnosis.12 Skeletal scintigraphy is able to 
demonstrate bone metastases several months before they are radiographically 
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identifiable, with a 5%-10% change in ratio of lesion to normal bone required to detect 
an abnormality.63,64 
 
The major advantages of skeletal scintigraphy can be summarised as: (1) high 
sensitivity for the detection of skeletal metastases; (2) whole body imaging capability; 
(3) relatively low cost; (4) ease of performance on almost any patient; (5) absence of 
significant toxicity or side effects; (6) relatively low total body radiation dose; (7) value 
as a guide for monitoring response to therapy, including palliative radionuclide 
therapy.11 
 
The disadvantages include low specificity and anatomical imprecision. Bone scintigrams 
may be negative in patients without cortical bone involvement, despite trabecular bone 
involvement.13 Small purely osteolytic lesions may also be missed on bone scans. 
 
SPECT-CT 
 
A SPECT/CT hybrid system acquires SPECT (Single Photon Emission Computed 
Tomography) images and CT images in one session in order to minimise 
misregistration. 
 
Some work has been done with the aim of evaluating the use of this hybrid system in 
bone disease. Römer and co-workers were able to clarify more than 90% of lesions 
previously classified as indeterminate on SPECT in a study using a SPECT/CT system 
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with a dual-head gamma camera and a dual-slice spiral CT component mounted within 
the same gantry.65 Improved localisation of skeletal lesions has been found to be 
especially useful in the spine, with better differentiation of vertebral abnormalities and 
better definition of the exact vertebra, or part of the vertebra affected.66 In addition, final 
scan interpretation is significantly altered in 23% of patients after SPECT/CT with 
impact being less in the appendicular skeleton. The impact also seems to be greater for 
patients being investigated for infection than for skeletal metastases, probably due to 
better demarcation between soft tissue and bone involvement. 
 
Utsunomiya and co-workers retrospectively studied the additional diagnostic value of 
fused SPECT and CT images in assessing possible skeletal metastases using 
separately acquired SPECT and CT images.67 They concluded that there was increased 
diagnostic confidence obtained with fused SPECT/CT images compared with separate 
sets of scintigraphic and CT images in differentiating malignant from benign lesions. 
The system used in this study was designed by the investigators and consisted of a 
dual-head, gantry-free gamma camera with a multi-detector row (diagnostic) CT system. 
Software co-registration algorithms were used for image fusion, using internal 
anatomical structures common to both modalities as reference points. The systems 
using diagnostic CT provide superior image resolution and allow separate assessment 
of bony structures. This however is at the cost of high radiation dose to the patient, with 
the radiation dose to a patient having a chest CT estimated at about 8mSv. 68 Potential 
for image misregistration arose in this study as fusion was done manually with 
successful co-registration confirmed by consensus of two radiologists. 
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SPECT/CT with a Millennium VG® Hawkeye™ system (GE Healthcare) has been 
shown to be a feasible technique yielding co-registered dual-modality images, allowing 
more precise interpretation of scintigraphic studies in various clinical situations.69 This 
same system has been evaluated in a study by Horger and co-workers to assess 
whether it could improve the differentiation between benign and malignant skeletal 
lesions.21 They concluded that combining SPECT and CT improved the diagnostic 
accuracy of bone scintigraphy significantly by identifying benign bone abnormalities. 
Eighty one percent of lesions that had initially been classified as indeterminate on 
SPECT were correctly diagnosed on SPECT/CT. The sensitivity of SPECT/CT for 
skeletal metastases in this study was not significantly higher than that of SPECT (98% 
vs. 94% p=0.63), whereas the specificity of SPECT/CT was significantly higher (81% vs. 
19% p=0.001). It would have been interesting if the data in this study had also been 
analysed on a patient-wise basis, in addition to the lesion-wise basis, so as to get an 
overall picture of how SPECT/CT influenced each patient’s diagnosis and probable 
subsequent management. This system is more widely available and the patient is 
subjected to a lower radiation dose as the CT component is single slice, with the trade-
off being lower image spatial resolution and increased noise. 
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CONVENTIONAL RADIOGRAPHY 
 
This modality has been the first line of investigation for metastatic disease for many 
years. It is still used for assessing clinically symptomatic areas and for areas identified 
as abnormal on bone scintigraphy. In this situation radiography assists in differentiating 
between a benign or malignant cause of symptoms or scintigraphic findings. X-rays are 
appropriate for imaging abnormalities of cortical and trabecular bone by detecting lytic, 
sclerotic and mixed-type lesions. Conventional radiography is useful in assessing the 
integrity of cortical bone and is able to depict early pathological fractures.70 Its 
advantage is that it is relatively affordable and readily accessible compared to other 
imaging modalities such as scintigraphy, Computed Tomography, and Magnetic 
Resonance Imaging. 
 
Conventional radiography, however, suffers from low sensitivity as there should be 30-
50% bone demineralisation in a lesion for it to be detected.45 Moreover, its use for an 
overall metastatic bone survey to identify foci of skeletal metastases has not been found 
to be cost-effective and is relatively insensitive for the detection of asymptomatic 
metastatic disease.38 Serial surveys are still being used for the assessment of 
progression of metastatic disease, although a survey limited to previously demonstrated 
areas of disease is probably more cost-effective. 
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COMPUTED TOMOGRAPHY (CT) 
 
CT is commonly used for further assessment of equivocal lesions suggested by bone 
scan and has an important role in identifying complications that may accompany 
malignant bone involvement. It has the advantage of providing information about 
metastatic deposits such as soft tissue extension, intraspinal spread of vertebral 
metastases, spinal canal compromise, and risk of pathological fracture.  It is widely 
used for the investigation of malignancy due to its good anatomic resolution, soft tissue 
contrast, and detailed morphology. Both cortical and trabecular bone components can 
be well defined and the sensitivity of CT for detecting bone metastases ranges between 
71% and 100%.52 The sensitivity of CT is superior to that of conventional radiography 
for the depiction of cortical bone involvement with a contrast resolution approximately 
ten times that of conventional radiography.42 CT is able to detect skeletal metastases 
before they are apparent on conventional radiography. Because it is able to provide 
good cross-sectional anatomic images, use of CT is beneficial when examining complex 
structures such as vertebrae. 
 
However, because considerable cortical destruction is required for visualisation of a 
metastasis by CT, the sensitivity in detecting early malignant bone involvement is still 
relatively low.71 Cortical destruction may be more difficult to determine in the presence 
of severe osteoporotic or degenerative changes.72 CT is not commonly used as a 
routine imaging modality for the survey of metastatic bone involvement, but is usually 
used for further assessment of equivocal lesions suggested by bone scintigraphy. The 
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sensitivity for assessment of malignant bone marrow infiltration is limited. Computed 
Tomography is also relatively expensive compared to conventional radiography and 
scintigraphy and delivers a high radiation dose to the patient. The effective dose 
equivalent to a patient undergoing conventional chest radiography is between 0.02-
0.05mSv while that to a patient undergoing chest CT is about 8mSv, up to four hundred 
times the dose from chest x-ray.68 The effective dose equivalent for a patient receiving 
99mTc-Methylene Diphosphonate (MDP) is 0.006mSv/MBq (4.4mSv for an adult dose of 
740MBq).73 It is also because of the magnitude of the radiation dose that a whole body 
skeletal survey for metastases is not normally done. 
 
Magnetic Resonance Imaging (MRI) 
 
Magnetic Resonance Imaging (MRI) has been shown to be superior to skeletal 
scintigraphy for in the evaluation of metastatic disease of bone marrow.44,74 The 
possible explanation for this is that haematogenously seeded intramedullary metastases 
produce detectable lesions by bone marrow replacement before intrinsic or reactive 
metabolic changes in cancellous and cortical bone can be detectable scintigraphically or 
radiographically.75 It has been found to have a sensitivity of up to 100% for the detection 
of bone marrow metastases.76 MRI is particularly useful for depicting spinal and pelvic 
metastases as well as providing additional information on extension of the tumour 
outside of the bony margins and evaluating the integrity of the spinal canal. 
 
 22 
MRI is, however, relatively expensive and is not widely available. Computed 
Tomography is more sensitive than MRI in evaluating cortical bone destruction, 
although MRI is more sensitive than CT for detecting bone marrow involvement.77 
Whole body MRI techniques are difficult to perform and are time-consuming, thereby 
making scintigraphy the preferred screening test for skeletal metastases as it examines 
the entire skeleton, and is less expensive.75 Although MRI is currently the best imaging 
technique for detecting marrow-based disease and for delineating the osseous and soft 
tissue extent of a bone tumour, it is not as useful as conventional radiography for 
characterising the aggressiveness of most bone lesions.78 The reason for this is that on 
both T1 and T2-weighted sequences on MRI, cortical bone appears black and thus 
cannot be adequately assessed with this modality.79 
 
 
POSITRON EMISSION TOMOGRAPHY (PET) 
 
Positron Emission Tomography is a nuclear medicine imaging modality characterised by 
high contrast resolution, whole body tomographic data acquisition and the ability to 
perform quantitation of tracer uptake. Some functional changes that occur in bone 
marrow and bone due to malignant infiltration may precede any structural changes that 
are required to visualise the presence of malignant bone involvement by morphologic 
imaging modalities. The PET tracers mostly used for assessment of malignant bone 
involvement are 18F-Fluoride and 18F-fluorodeoxyglucose (18F-FDG). 
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18F-FLUORIDE 
 
18F-Fluoride was first introduced as a bone imaging agent in 1962.80 The mechanism of 
uptake is similar to that of Methylene Diphosphonate. After diffusion into bone 
extracellular fluid, fluoride ions exchange with –OH groups in the hydroxyapatite crystal 
to form Fluoroapatite, which is deposited mainly at the surface where bone remodelling 
and turnover are greatest. Uptake reflects increased regional blood flow and is higher 
than that of MDP (up to a factor of 2). 18F-Fluoride has minimal protein binding and 
hence higher capillary permeability and faster blood clearance leading to better target-
background ratio. The regional plasma clearance is reported to be 3 to 10 times higher 
in bone metastases compared to normal bone.64,81,82 
 
Increased 18F-Fluoride uptake may be detected in both sclerotic (osteoblastic) and lytic 
lesions, demonstrating higher sensitivity than MDP for detection of lytic lesions. 
Schirrmeister and co-workers reported that 18F-Fluoride PET detected bone metastases 
overlooked by bone scan in patients with lung cancer, as well as all metastatic lesions 
diagnosed by MRI.83 It is, however, not a routine imaging modality for detecting 
malignant bone involvement, with use primarily suggested in patients at high risk for 
metastatic bone disease where bone metastases are suspected but bone scan is 
negative. 18F-Fluoride PET is also indicated in patients with a tumour type that has 
predominantly lytic bone lesions such as multiple myeloma.64,60,83 
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18F-Fluoride PET has the drawback of limited specificity because uptake of the Fluoride 
is also demonstrated in benign bone pathology. It is prone to a higher incidence of false-
positive sites of uptake than bone scan with MDP.81 Lesions detected may require 
correlation with CT or MRI for further validation. The use of hybrid systems e.g. PET/CT 
may improve the specificity of 18F-Fluoride PET by determining the morphology of the 
scintigraphic lesion on the CT data of the study.84 
 
18F-FLUORODEOXYGLUCOSE (FDG) 
 
Fluorodeoxyglucose (FDG) is an analogue of glucose which is taken up avidly by highly 
metabolic tissue, including some malignancies. FDG is taken up into cells by glucose 
membrane transporter proteins that are over-expressed in many tumour cells. It 
undergoes the first step of phosphorylation but is not metabolised further, resulting in its 
intracellular accumulation.  It has been successfully used in combination with CT as a 
functional, morphological examination method in the routine clinical evaluation of some 
oncological patients.5 
 
18F-FDG PET is used in the staging of malignant tumours and in monitoring tumour 
response to therapy. Normal red marrow usually demonstrates low-intensity FDG 
uptake, thereby assisting in detecting increased uptake in early marrow involvement 
before an identifiable bone reaction.85 A study by Ohta and co-workers found 18F-FDG 
PET to be statistically superior in specificity to bone scintigraphy in the diagnosis of 
bony metastases from breast carcinoma, concluding that it was a powerful tool in the 
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diagnosis of bony metastases in such patients.86 It also has the advantage of detecting 
both soft-tissue and skeletal disease. Some data suggests that 18F-FDG PET is more 
sensitive in detecting lytic metastases than sclerotic lesions.87 Sclerotic metastases 
show uptake of lower intensity compared with lytic lesions, sometimes no increased 
uptake at all. Bone scintigraphy appears to have a complementary role to that of 18F-
FDG PET as most lesions that are non-18F-FDG-avid (mostly blastic) will show uptake 
on bone scintigraphy while those that do not show uptake on bone scintigraphy (mostly 
lytic) will show uptake on 18F-FDG PET.  If the primary tumour is not FDG avid, 18F-FDG 
PET is not considered a suitable modality for staging but rather bone scintigraphy. 
Failure to detect metastases in these cases may be unrelated to their localisation in 
bone or their sclerotic nature but to reflect the non-FDG avidity of the individual 
tumour.12 Other studies have shown that 18F-FDG PET is less sensitive than skeletal 
scintigraphy in detection of bone metastases in cases of prostate cancer and 
osteosarcoma.88,89 
 
18F-FDG may also accumulate in non-malignant sites such as areas of infection, leading 
to false-positive findings. Significant problems also arise in patients on bone marrow 
stimulating medication in which there will be areas of increased 18F-FDG uptake even 
without tumour involvement. PET services are relatively expensive to run and are not 
readily available, thereby limiting the use of 18F-FDG PET as a routine investigation tool 
for skeletal metastases. 
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AIM OF THE STUDY 
 
The aim of this research is to investigate the added value of SPECT/CT imaging in the 
evaluation of equivocal skeletal lesions in patients known to have primary malignant 
disease. 
 
OBLECTIVES 
 
1. To assess the added value of SPECT/CT over SPECT alone on 
a. Lesion-wise and 
b. Patient-wise basis in the evaluation of equivocal lesions. 
 
2. To establish the appropriate clinical indications for skeletal SPECT/CT imaging in 
patients with known malignant disease. 
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CHAPTER 3 
 
SUBJECTS AND METHODS 
PATIENT SELECTION 
 
Forty two patients were included in the study prospectively between April 2007 and April 
2008. Participant recruitment was carried out from the day to day referrals of patients 
with known malignant disease, undergoing routine bone scanning for screening or 
follow-up, regardless of primary tumour location or histological type. Patients who 
showed skeletal lesions on planar scintigraphy that could not be confidently classified 
as either malignant or benign were included in the study. No individual patient had more 
than one study included in the study. 
 
The study was approved by the Stellenbosch University Faculty of Health Sciences 
Ethics Committee for Human research and written informed consent was obtained from 
each patient before inclusion in the study. 
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IMAGE ACQUISITION 
 
Planar scans were obtained 3 hours after intravenous injection of 740MBq of 99mTc-
Methylene Diphosphonate (99mTc-MDP). Planar imaging was done using one of six 
gamma cameras, two single head cameras (GE Starcam™ and Elscint SP4™) and four 
dual-head gamma cameras (two Elscint Helix™ and two GE Infinia cameras, one of 
which is the Hawkeye™), each equipped with high-resolution, low-energy collimators. 
Whole body planar images on the single head cameras were acquired in the form of 
multiple static images over different regions of the body. A 256×256 matrix was used 
with 700 000 counts being counted per image in the axial skeleton and 300 000 to 500 
000 counts per image in the appendicular skeleton. On the dual head Elscint Helix™ 
cameras, a step-and-shoot mode was used and counting done for 200 seconds per step 
on a 512×256 matrix. The number of steps depended on the patient’s height. Whole 
body planar imaging on the GE Infinia cameras was done in a continuous mode at a 
rate of 10cm per minute on a 512×256 acquisition matrix. 
 
 
One or more SPECT/CT volumes were chosen following a visual assessment of the 
whole body planar scan. Volumes were selected to include all equivocal planar lesions 
in the field of view, irrespective of the location of the lesions in the skeleton.  SPECT 
imaging was done on the two Elscint Helix dual head cameras using a 128×128 matrix 
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and a 6º step-and-shoot mode with counting done at 20 seconds per step. Each head 
was set to rotate through 180º for a total 360º SPECT acquisition. The CT component of 
the SPECT/CT acquired on the GE Infinia Hawkeye™ was done with an X-Ray tube 
mounted within the same gantry on a 256×256 matrix, voltage 140kV and current 
2.5mA. Acquisition slice thickness was 10mm with rotation velocity set at 2.6rpm. 
 
Processing of SPECT and SPECT/CT images was done on the Xeleris™ and 
Hermes™ workstations by iterative reconstruction and fusion of SPECT and CT images 
was done automatically on the same workstations. The Butterworth filter was used for 
SPECT images while a Hann filter with a cut-off frequency of 1.0 was applied to the CT 
data. 
 
DATA/IMAGE ANALYSIS 
 
Nuclear Medicine images (planar images and SPECT) were evaluated by two Nuclear 
Medicine Physicians with interpretations by consensus. All lesions noted within the 
SPECT/CT volume(s) were interpreted, including any new lesions only visible on 
SPECT. The planar images were initially used to determine the volume(s) that would be 
assessed using SPECT/CT. The Nuclear Medicine Physicians then evaluated the 
planar and SPECT images blinded to the CT study. Lesions were classified as benign, 
malignant or equivocal. Lesions were classified as equivocal if they could not be 
confidently assigned as being either malignant or benign. Similarly a classification of 
benign, malignant, or equivocal, was made for the patient’s overall status for bone 
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metastases. This scoring was done in the light of all available clinical information, 
including a brief history of each patient, laboratory results, primary tumour, and any 
treatment given to the patient to date. 
 
SPECT/CT images were then re-evaluated by the nuclear medicine physicians together 
with an experienced diagnostic radiologist. All lesions and patients were then 
reclassified using the same system. The CT images obtained from the SPECT/CT were 
also analysed for any additional abnormalities at sites other than those identified on the 
bone scan. 
 
VALIDATION OF SPECT AND SPECT/CT INTERPRETATION 
 
A final decision as to the true status of lesions was made after consideration of the 
clinical information, including a follow up period of 6-9months. When available, 
additional radiological studies (CT, Radiographs, and MRI) performed within 3months of 
the bone scan, were used to reach the overall decision, as well as follow-up bone scan 
in some patients. Change in character and/or size on radiological studies was 
considered to indicate malignancy, whereas a lesion was considered benign if there 
was no change. Lesions which showed increase in size and/or intensity of 99mTc-MDP 
uptake on follow-up bone scan were considered to be malignant. Those which remained 
unchanged over at least 9months without therapy were considered benign. A lesion that 
decreased or increased in size and/or intensity on cytotoxic therapy was considered to 
be malignant. 
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STATISTICAL ANALYSIS 
 
The proportion of equivocal interpretations on SPECT and SPECT/CT, as well as the 
accuracy of each were compared on both a patient-wise and lesion-wise basis. In order 
to calculate the accuracy of SPECT and SPECT/CT, equivocal lesions were considered 
to indicate malignancy. Ninety five percent confidence intervals (CIs) were used in the 
estimations and comparison was done using McNemar Chi-square test for matched 
pairs, and Mosteller’s Chi-square test for small samples when n<20. SPECT and 
SPECT/CT results were each compared to the gold standard in order to compare the 
performance of each. 
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CHAPTER 4 
 
RESULTS 
 
SPECT and SPECT/CT were performed on 42 patients all with histologically confirmed 
malignant disease. Twenty-eight of these patients were women, and 14 were men, 
ranging in age between 28 years and 79 years (mean age 58 years). The primary 
malignancies included in this sample were 22 breast (52%), 8 prostate (19%), four 
bronchus, and one each of bladder, oesophageal, chordoma, chondrosarcoma, 
osteosarcoma, nasopharyngeal, colorectal, and vulva cancer (Table 1). There were 
twenty-nine patients included in the study who described having bone pain at the time of 
the bone scan. 
Table 1: Frequency Table of Tumour type 
Tumour Type Count Percent 
Breast Ca 22 52.4% 
Prostate Ca 8 19.0% 
Bronchial Ca 4 9.5% 
Osteosarcoma 1 2.4% 
Oesophageal Ca 1 2.4% 
Chondrosarcoma 1 2.4% 
Bladder Ca 1 2.4% 
Chordoma 1 2.4% 
Colorectal Ca 1 2.4% 
Vulva Ca 1 2.4% 
Nasopharyngeal Ca 1 2.4% 
TOTAL 42 100% 
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Diagnostic radiology (X-Rays, CT, or MRI) was available for all patients at the time of 
review of records, which was done between six and nine months after SPECT/CT 
acquisition. None of the participants had biopsy of equivocal lesions. Three patients had 
MRI of the regions containing equivocal lesions, three had repeat bone scans, seven 
had Computed Tomography (CT), and 29 had X-Rays. The final decision as to whether 
the patient had malignant or benign disease at the sites demonstrated on the bone scan 
was made after reviewing this information, as well as clinical information that included 
laboratory results such as rising serum calcium levels. This was then used to make a 
final decision regarding the status of lesions which was then used as a gold standard for 
this study. Based on this 24 patients were diagnosed as having benign bone disease 
(57%) while 18 had malignant bone disease (43%) (Table 2). 
Table 2: SPECT, SPECT/CT interpretation, and Gold Standard, patient-wise 
Pt Tumour Type Age(Yrs) Sex SPECT SPECT/CT G S Bone Pain 
1 Osteosarcoma 53 M M M M Y 
2 Bronchial Ca 69 M E B B Y 
3 Breast Ca 52 F B B B Y 
4 Breast Ca 64 F E B B N 
5 Breast Ca 65 F E E B N 
6 Breast Ca 52 F M M M Y 
7 Breast Ca 75 F M M M N 
8 Oesophageal Ca 72 M M M M Y 
9 Prostate Ca 63 M M M M Y 
10 Breast Ca 77 F E B B N 
11 Breast Ca 54 F E M M N 
12 Breast Ca 55 F M M M Y 
13 Breast Ca 48 F M M M N 
14 Prostate Ca 55 M E E B Y 
15 Breast Ca 67 F E E B N 
16 Breast Ca 69 F E B B N 
17 Breast Ca 63 F B B B Y 
18 Prostate Ca 55 M E B B Y 
19 Prostate Ca 65 M M M M Y 
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20 Prostate Ca 59 M M M B Y 
21 Breast Ca 55 F M M M Y 
22 Prostate Ca 73 M E M B N 
23 Chondrosarcoma 39 F M M M Y 
24 Bladder Ca 56 F M M M Y 
25 Chordoma 56 F B B B Y 
26 Breast Ca 47 F M M B N 
27 Bronchial Ca 59 M B B B Y 
28 Breast Ca 55 F E B B Y 
29 Breast Ca 39 F E M M N 
30 Breast Ca 48 F E B B Y 
31 Breast Ca 49 F E B B N 
32 Breast Ca 43 F B B B N 
33 Breast Ca 58 F B M M Y 
34 Colorectal Ca 62 F M M M Y 
35 Prostate Ca 69 M E B B Y 
36 Prostate Ca 82 M E E B Y 
37 Breast Ca 57 F E E B Y 
38 Vulva Ca 64 F E M M Y 
39 Nasopharyngeal 28 M M E B Y 
40 Breast Ca 43 F M M M Y 
41 Bronchial Ca 62 F E M M Y 
42 Bronchial Ca 59 M E B B Y 
 
M-Malignant  B-Benign E-Equivocal  Y-Yes  N-No GS-Gold 
Standard 
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PATIENT-WISE ANALYSIS 
 
SPECT 
 
Using SPECT on a patient-by-patient basis, six patients were interpreted as having 
benign bone disease, 16 as having malignant bone disease, and 20 patients (47%) 
were equivocal (Table 2). Three of the patients described as having malignant disease 
on SPECT were found to have benign disease based on the gold standard. One of the 
patients described as having benign disease was found to have malignant disease 
based on the gold standard. Of the 20 patients described as being equivocal on 
SPECT, 16 were found to be benign, and 4 were found to be malignant based on the 
gold standard. 
 
SPECT/CT 
 
Fifteen patients were interpreted as having benign bone disease on SPECT/CT while 21 
were malignant and 6 (14%) had equivocal diagnoses (Table 2). There were three 
patients who had malignant diagnoses on SPECT/CT found to be benign based on the 
gold standard, while no patient was upgraded from benign to malignant. All of the 
equivocal patients on SPECT/CT were found to have benign disease. 
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Table 3: Patient-wise proportion of equivocal interpretations for SPECT versus 
SPECT/CT: 
 
For all patients SPECT-CT was found to result in significantly fewer equivocal patient 
studies compared to SPECT alone (p=0.00115) (Table 3). This was also true for 
subgroups with and without bone pain, and those with breast and prostate carcinoma. 
Compared to SPECT, SPECT-CT was found to alter the interpretation of 17 patients 
(40%). Equivocal interpretations on SPECT in 10 patients were altered to benign on 
SPECT/CT, all of which were found to be benign based on the gold standard. In 5 
patients equivocal interpretations were altered to malignant, 4 of which were found to be 
malignant and one found to be benign based on the gold standard. In another patient a 
benign interpretation was altered to malignant, which was found to be malignant based 
on the gold standard. A malignant interpretation was altered to equivocal in a single 
patient, which was found to be benign based on the gold standard. 
    SPECT SPECT/CT   
  n Equivocal % Equivocal % Statistical Test p-value 
Total 42 20 48 6 14 McNemar Χ² 0.00115 
Bone Pain 29 11 38 4 14 McNemar Χ² 0.04550 
No Bone Pain 13 9 69 2 15 Mosteller’s <0.0001 
Breast Ca 22 11 50 3 14 McNemar Χ² 0.01333 
Prostate Ca 8 5 63 2 25 Mosteller’s <0.0001 
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Table 4: Patient-wise accuracy for SPECT versus SPECT/CT:  
 
 
 
 
 
 
 
When equivocal studies on both SPECT and SPECT/CT were taken to indicate 
malignancy, the accuracy of SPECT/CT (79%) was significantly greater than that of 
SPECT (52%) (p=0.0026) (Table 4). This was also true for subgroups with and without 
bone pain, and those with breast and prostate carcinoma. 
 
In three patients there were lytic lesions detected on SPECT/CT that were not seen on 
SPECT. In one case, the patient was reclassified as having malignant disease on 
SPECT/CT and gold standard after being classified as having benign disease on 
SPECT. In the other two patients there was no alteration in the overall diagnoses as 
there were other malignant osteoblastic lesions detected. 
 
    SPECT SPECT/CT     
  n Correct % Correct % Statistical Test p-Value 
Total 42 22 52 33 79  McNemar Χ² 0.0026 
Bone Pain 29 17 59 24 83  McNemar Χ² 0.0233 
No Bone Pain 13 5 38 9 69  Mosteller’s <0.0001 
Breast Ca 22 11 50 18 82  McNemar Χ² 0.0233 
Prostate Ca 8 2 25 4 50 Mosteller’s <0.0001 
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LESION-WISE ANALYSIS 
 
SPECT 
 
The forty-two patients who underwent imaging had 189 lesions detected on planar 
scintigraphy and on SPECT alone (Table5). Eighty-six lesions were interpreted as 
benign on SPECT while 45 were malignant and 58 (31%) were equivocal. Of the 58 
equivocal lesions, forty-eight were diagnosed as benign and ten as malignant on gold 
standard. Eight of the 45 lesions that were interpreted as malignant on SPECT were 
found to be benign on gold standard while 4 of the 86 that were interpreted as benign 
were found to be malignant. 
 
Table 5: SPECT interpretation, and Gold Standard, lesion-wise 
Gold Standard Interpretation SPECT Interpretation 
Benign Malignant 
Benign 86 82 4 
Malignant 45 8 37 
Equivocal 58 48 10 
Total 189 138 51 
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SPECT/CT 
 
On SPECT/CT, forty-six lesions were interpreted as malignant and 126 as benign while 
17 (9%) remained equivocal (Table 6). Twelve of the equivocal lesions were found to be 
benign on gold standard while 5 were malignant. Forty-four of the 46 malignant lesions 
on SPECT/CT were also found to be malignant on gold standard with two being 
downgraded to benign. Only one of the 126 lesions interpreted as benign on SPECT/CT 
was found to be malignant on gold standard. The diagnosis was not altered in the other 
125 benign lesions. The skeletal region with the greatest proportion of equivocal lesions 
on both SPECT and SPECT/CT was the vertebral column (62% and 53% of equivocal 
lesions respectively). 
 
Table 6: SPECT interpretation, and Gold Standard, lesion-wise 
Gold Standard Interpretation SPECT/CT Interpretation 
Benign Malignant 
Benign 126 125 1 
Malignant 46 2 44 
Equivocal 17 12 5 
Total 189 139 50 
 
For all lesions taken together SPECT/CT led to a significant reduction in the number of 
equivocal lesions when compared to SPECT alone (p<0.0001), altering the 
interpretation of 56 lesions (30%) (Table 7). The reduction in the number of equivocal 
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lesions was also significant for all regions of the skeleton except the lumbar spine 
(p=0.22067). However, the reduction was significant when the entire vertebral column 
was considered as a single region (p<0.0001). 
 
Table 7: Lesion-wise proportion equivocal 
 
    SPECT SPECT/CT   
  n Equivocal % Equivocal % Statistical Test p-Value 
Total 189 58 31 17 9 McNemar Χ² <0.0001 
Skull 5 1 2 0 0 Mosteller’s <0.0001 
Chest Wall 38 15 39 5 13 McNemar Χ² 0.00938 
Cervical Spine 16 7 44 0 0 Mosteller’s <0.0001 
Thoracic Spine 63 15 24 2 3 McNemar Χ² 0.00195 
Lumbar Spine 37 9 24 5 14 McNemar Χ² 0.22067 
Sacrum 13 5 38 2 15 Mosteller’s <0.0001 
Vertebral Column 129 36 28 9 7 McNemar X² <0.0001 
Pelvis 6 2 33 1 17 Mosteller’s <0.0001 
Extremities 11 4 36 1 9 Mosteller’s <0.0001 
 
For all lesions taken together the accuracy of SPECT/CT was found to be significantly 
higher than that of SPECT when equivocal lesions were interpreted as indicating 
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malignancy (p<0.0001) (Table 8). This also applied to all other regions of the skeleton 
except the skull where statistical analysis was not applied since there was no difference 
between the accuracy of SPECT and SPECT/CT in this region. 
 
Table 8: Lesion-wise accuracy for SPECT versus SPECT/CT: 
 
    SPECT SPECT/CT     
  n Correct % Correct % 
Statistical 
Test P-Value 
Total 189 126 67 174 92 McNemar Χ² <0.0001  
Skull 5 4 80 4 80 Not Done  
Chest Wall 38 25 66 34 89 McNemar Χ² 0.0077 
Cervical Spine 16 9 56 15 94 Mosteller’s <0.0001 
Thoracic Spine 63 43 68 61 97 McNemar Χ² <0.0001 
Lumbar Spine  37 28 76 35 95 McNemar Χ² 0.0233 
Sacrum 13 6 46 10 77 Mosteller’s <0.0001 
Vertebral Column 129 86 67 121 94 McNemar Χ² <0.0001 
Pelvis 6 4 67 5 83 Mosteller’s <0.0001 
Extremities 11 7 64 10 91 Mosteller’s <0.0001 
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CHAPTER 5 
 
DISCUSSION 
 
In this study, we found that SPECT/CT results in fewer equivocal diagnoses and 
increased accuracy compared to SPECT on both a patient-wise and lesion-wise basis. 
Where SPECT/CT resulted in a change in a patient’s diagnosis, most of the time it was 
downgrading rather than upgrading the diagnosis. We found that SPECT/CT has a high 
negative predictive value for skeletal metastases, although further investigations may be 
required in order to reduce the number of false-positive diagnoses. It was also shown 
that SPECT/CT increases the proportion of correct diagnoses compared to SPECT and 
that its benefit seems to be independent of the presence of bone pain or the type of 
primary tumour. The addition of the CT component in SPECT/CT in the lumbar spine 
does not improve the diagnostic confidence in equivocal lumbar lesions significantly, 
however it does improve accuracy in this region. As far as the author is aware this is the 
first study addressing in impact of SPECT/CT in bone metastases on a patient-wise 
basis, as well as studying different regions of the skeleton separately. 
 
On SPECT/CT, there was a decrease in the number of patients diagnosed as having 
malignant or equivocal bone disease which were benign on gold standard, with 9  
patients on SPECT/CT as opposed to 19 patients with SPECT being downgraded to 
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benign on gold standard. This result indicates that, while the results are better than 
SPECT, further investigations may be required in order to further reduce the number of 
false-positive diagnoses in patients with malignant bone disease based on SPECT/CT. 
The fact that no patient was upstaged from benign to malignant suggests a high 
negative predictive value for SPECT/CT. This would however need to be corroborated 
by a study involving a larger patient population. SPECT/CT resulted in significantly 
fewer equivocal diagnoses compared to SPECT in the whole patient sample studied 
(p=0.0015) as well as in subgroups with and without bone pain (p=0.0455 and p<0.0001 
respectively) and in those with breast (p=0.01333) and prostate cancer (p<0.0001). 
These data support the use of SPECT/CT for improving diagnostic confidence when 
investigating cancer patients for skeletal metastases as found by other groups.21,65,66,67 
Because bone pain is the most common neurologic symptom, and sometimes the only 
presenting symptom in malignancy, we also sought to investigate the implication, if any, 
of the presence or absence of bone pain on the diagnoses of bone metastases using 
SPECT/CT in cancer patients.90,91,92 It is interesting to note is that regardless of whether 
or not patients complain of bone pain, there is a significant reduction in the number of 
equivocal diagnoses and a significant increase in accuracy from SPECT to SPECT/CT. 
This implies that if an equivocal lesion is detected in a patient with or without bone pain, 
SPECT/CT must be performed in all cases. With breast and prostate cancer the benefit 
of SPECT/CT was also present when looking at these groups separately, suggesting 
that its additional value may also be independent of the underlying primary tumour. 
 
The diagnosis was altered in 17 out of 42 patients (40.5%) which is consistent with the 
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results of Roach and co-workers who recorded an alteration in 56% of patients in their 
study.66 Of the seventeen patients in whom the diagnosis was altered by SPECT/CT, 
fourteen had correct diagnoses (true positive and true negative) while two were 
incorrect (false negative and false positive) and a single patient remaining with an 
equivocal diagnosis after SPECT/CT. This further strengthens the grounds for the use 
of SPECT/CT because the diagnoses were correctly altered in the vast majority (82%) 
of patients in whom there was a change. In terms of accuracy, a similar trend was 
observed as that seen in the reduction of equivocal lesions. SPECT/CT showed 
significantly greater accuracy compared to SPECT alone in the total patient sample 
(p=0.0026) and in the subgroups of patients with and without bone pain (p=0.0233 and 
p<0.0001 respectively) as well as for patients with breast (p=0.0233) and prostate 
cancer (p<0.0001). These statistics also support the use of SPECT/CT in the 
investigation of cancer patients for metastatic bone disease as it increases the 
proportion of correct diagnoses compared to SPECT. 
 
In the lesion-wise analysis we observed how SPECT/CT influenced the interpretation of 
each skeletal lesion. There were 189 lesions seen on SPECT alone with 58 (31%) of 
these being equivocal. Of the 86 benign SPECT lesions, four were false-negative while 
eight of the 45 malignant SPECT lesions were false-positive. This implies that SPECT 
was correct 90% of the time in the 69% of cases in which a diagnosis could be reached. 
SPECT/CT resulted in fewer equivocal lesions than SPECT, with a diagnosis being 
reached in 91% of lesions. Furthermore, SPECT/CT was correct 98% of the time that a 
diagnosis could be reached. Consequently SPECT/CT resulted not only in fewer 
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equivocal lesions, but also in increased accuracy in the interpretation of these lesions, 
further supporting its use. Overall, SPECT/CT significantly reduced the number of 
equivocal skeletal lesions compared to SPECT from fifty-eight (31%) to seventeen (9%) 
(p<0.0001). 
 
Although SPECT/CT resulted in a statistically significant reduction in the proportion of 
equivocal lesions detected in the vertebral column as a whole (p<0.0001), as well as in 
the cervical, thoracic and sacral vertebrae, this reduction was not significant when the 
lumbar spine was considered separately (p=0.22067). This may be due to the larger 
size of lumbar vertebrae which facilitates more accurate localisation of lesions, enabling 
them to be classified as benign or malignant with SPECT alone more easily. 
Consequently the addition of the CT component in SPECT/CT may not improve the 
diagnostic confidence in equivocal lumbar lesions significantly. Other skeletal regions 
such as the skull, pelvis, chest wall and extremities also showed a significant reduction 
in the number of equivocal lesions on SPECT/CT compared to SPECT.  Although 
usually reserved for investigating complex structures such as vertebrae, these results 
suggest that SPECT/CT is of benefit when investigating other skeletal regions including 
the chest wall. This skeletal region is of particular concern because computed 
tomographic images undergo degradation due to motion artefact as well as higher 
incidence of SPECT and CT misregistration.67 The accuracy of SPECT/CT was shown 
to be significantly superior to that of SPECT in most skeletal regions except the skull 
where the accuracy of the two modalities was the same. This statistic should, however 
be considered with caution due to the small number of lesions detected in the skull. 
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On a patient-wise basis, even in patients with a decisive diagnosis on SPECT, there 
was a change in the number of patients diagnosed as both malignant and benign. This 
change affected similar proportions of patients who had malignant bone disease on 
SPECT (3/15), compared to those with benign disease (1/6). This suggests that in 
addition to equivocal diagnoses, patients who have unequivocal diagnoses on SPECT 
(i.e. lesions with a decisive diagnosis) may still require further investigation with 
SPECT/CT as there is still a significant possibility of a false-positive and false negative 
diagnosis.  
 
 
The diagnosis of a lesion as malignant or benign on bone scan or other modality may 
have a significant influence on the management of a patient. The presence of skeletal 
metastases may indicate short patient survival time and a need for additional or 
intensified treatment.93 In lung cancer, for example, it may determine whether a patient 
undergoes surgical lobectomy or pneumonectomy, or palliative chemotherapy and/or 
radiotherapy. In a symptomatic patient with bone metastases, therapy may be tailored 
to include radiotherapy of the symptomatic metastatic lesion(s) in order to control the 
pain, or to prevent pathological fractures if weight-bearing bones are involved. If, 
however the pain is attributed to a benign lesion, appropriate less aggressive therapy 
may be indicated. 
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Bone scintigraphy is the most frequently performed study in most nuclear medicine 
departments, commonly being used in the evaluation of cancer patients for both staging 
and follow-up. It is a very sensitive modality that can be used for whole-body screening 
for the presence of skeletal metastases in many cancer patients. The specificity of bone 
scintigraphy in the diagnosis of skeletal metastases is not as high however, because 
most patients may also have benign skeletal disorders which may be difficult to 
differentiate from malignancy on scintigraphy alone.94,95,4 This is particularly true for 
vertebral lesions where the superimposition of structures on planar scintigraphy results 
in difficulty in locating lesions to particular vertebral sites. The addition of SPECT has 
led to a significant improvement in our ability to locate lesions on bone scintigraphy. The 
problem of superimposition of overlying activity with planar scintigraphy is minimised by 
using SPECT, which also enables more accurate anatomical localisation of lesions and 
easier differentiation between benign and malignant lesions. SPECT has become 
broadly available in most centres and several single photon emitting 
radiopharmaceuticals have been demonstrated to be of clinical value in a wide variety of 
neoplasms, including bone.96  Due to its superior contrast, SPECT also leads to the 
visualisation of lesions that may not have been seen on planar scintigraphy. This 
enables the detection of lesions that will initially have been invisible or equivocal on 
planar scintigraphy. However, the status of some lesions remains unclear after SPECT. 
 
The integration of Computed Tomography (CT) in the same gantry with a dual-head 
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camera system (SPECT/CT) has led to improved diagnostic accuracy compared to 
SPECT alone.67 SPECT/CT serves as a method of correlating anatomical information 
from CT with functional information from SPECT, hence enabling more accurate 
localisation and characterisation of SPECT lesions using the CT component. This is of 
great benefit in complex structures such as vertebrae where the location of a lesion 
determines whether it is classified as malignant or benign (e.g. pedicle or facet joint 
respectively).58In addition, a small number of purely lytic lesions that are not normally 
visible on bone scintigraphy may be seen on the CT images, despite the relatively poor 
CT quality of many commonly available SPECT/CT systems. 
 
Despite its advantages over SPECT alone, SPECT/CT still results in some lesions 
remaining equivocal. A disadvantage of SPECT/CT performed using a system similar to 
that used for this study, is that it results in additional imaging time of about fifteen 
minutes per volume imaged, thereby reducing patient throughput. It is notable that this 
study was performed using a low dose localising CT, which may be relevant if 
SPECT/CT is to be used more routinely in these patients in future. Though minimal, the 
CT component of SPECT/CT results in additional radiation dose burden to the patient in 
the order of about 0.5mSv.97 This is relatively low when compared to conventional CT 
which subjects a patient to an effective dose of 5-15mSv depending on the region of the 
body being scanned.68 These drawbacks are however acceptable when considering the 
significant reduction in equivocal findings and enhanced accuracy of performing these 
studies. 
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The six to nine month period that was chosen for follow-up in this study was used 
because it allowed enough time for updating of patient records and because repeat 
bone scans are often performed at least three months after the initial scan. During this 
period, benign lesions commonly remain unchanged whereas the appearance of 
malignant lesions may change, depending on the aggressiveness of the tumour, 
whether or not therapy has been administered, the amount of time elapsed after 
therapy, and the response to therapy. When chemotherapy has been administered to a 
patient with malignant bone disease, a flare response may occur in which uptake of 
99mTc-MDP will be increased in intensity and/or extent due to reparatory processes 
taking place.60,77,61,98,99,100 The increase in extent may be a result of the artefactual 
effect of increased intensity. Sometimes lesions that would not have been visible initially 
may become apparent on follow-up scan. This phenomenon may be evident up to six 
months post-therapy and may erroneously be interpreted as indicating progression of 
malignant bone disease. Interpretation of studies was done with this possibility in mind, 
and taking into consideration clinical information regarding recent therapy in order to 
minimise incorrect interpretation. A positive response to chemotherapy may also be 
seen as a reduction in the intensity of 99mTc-MDP uptake and/or a reduction in the 
number of lesions seen on bone scan. If radiotherapy has been administered to skeletal 
lesions, the region of the skeleton subjected to radiation will initially be seen as a 
photopenic area which later shows increased tracer uptake during repair. If therapy has 
not been given, malignant lesions may show increased intensity and/or extent of tracer 
uptake compared to the baseline study due to progression of malignant skeletal 
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disease, sometimes with evidence of new lesions. There may be difficulties in 
differentiating between a flare response and progression of malignant skeletal disease 
as both are characterised by similar scintigraphic features. This problem may be 
alleviated by repeating the bone scan at a later date, usually set at three months. Some 
tumours have predominantly lytic skeletal metastases which may not be visualised on 
bone scan. A repeat bone scan after therapy may however show evidence of these 
lesions as a flare response. Depending on their size, lytic lesions may be seen on the 
CT component of SPECT/CT, hence reducing the number of false negative studies. 
 
LIMITATIONS 
 
The selection of lesions used in this study is complex due to the nature of the 
techniques involved. Initially planar images were used to identify equivocal lesions, the 
location of which determined the location of SPECT/CT volumes. As a result some of 
these lesions remained equivocal, and some were considered benign or malignant on 
SPECT. In addition the volumes may have included other lesions already considered 
benign or malignant on planar imaging. A third group of lesions that were seen on the 
SPECT study were those that were not seen on the planar study, but also happened to 
be located in the SPECT/CT volumes. This study did not analyse these different 
subgroups of lesions to determine whether the additional value of SPECT/CT varied 
between them. 
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The gold standard used in this study had some weaknesses which included the fact that 
none of the patients imaged had biopsy done to establish the diagnoses of equivocal 
SPECT lesions. The study done by Horger and co-workers, which had similarities to 
ours, had biopsies done in five patients while in some, radiologic follow-up was used (37 
patients).21 Radiological studies used in this case included conventional radiography, 
CT and MRI. In our study as well as in Horger’s study, most patients underwent 
radiological studies as follow-up probably due to the ready availability and relative low 
cost of radiography and CT when compared to MRI. A major limitation was the lack of 
common gold standard criteria for the establishment of the correct diagnosis. It would 
have been ideal to use the same gold standard in all patients, but this became 
impractical because the decision of which investigational modality to use in determining 
the correct diagnosis was left to the referring physician(s). Our study also lacked any 
histopathologic analysis to confirm the diagnoses. We relied on radiologic follow-up and 
assessment of clinical information.  
 
Additionally, since the study was carried out over a one year period, the interpretation of 
patient studies may not have been done uniformly by the same readers when 
comparing the initial studies with those done towards the end of the study. Studies done 
towards the end may have lower incidence of equivocal lesions as the readers will have 
acquired more experience as the study progressed and would have been more decisive 
in making their interpretations. 
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Another limitation was the relatively small number of patients in our sample leading to 
low statistical power of most of our statistical analyses. Most of the literature reviewed to 
date shows a similar weakness of relatively low patient numbers.21,65,66,67 Because only 
a single SPECT/CT system is available in our department, the number of patients 
recruited for the study had to be limited in order to allow for use of the system for other 
clinical work. This issue is also a major challenge in most nuclear medicine centres in 
the developing world where SPECT/CT is not yet widely available. However, this was 
not considered as a major issue since, except for the lumbar spine, most of our results 
were significant. There may be some benefit in performing a larger series specifically 
looking at the impact of SPECT/CT when assessing lumbar spinal lesions. 
 
CONCLUSION 
 
SPECT/CT performs significantly better than SPECT alone for the interpretation of 
lesions in all regions of the skeleton. However, it may contribute less in the lumbar 
spine, therefore if facilities are limited, it may be reasonable to use SPECT only for 
equivocal lumbar lesions in most of which the use of SPECT gives a correct diagnosis 
after consideration of the pattern and intensity of tracer uptake. There is no evidence 
that this finding is dependent on the primary tumour, or the presence of bone pain. 
These findings were made both in terms of patients and individual lesions.  
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RECOMMENDATIONS 
 
1. The results of this study support the use of SPECT/CT in all cases of malignant 
disease that are being investigated for metastatic malignant bone disease where 
equivocal lesions exist on planar scintigraphy. 
2. Due to the limited availability of SPECT/CT technology, selection criteria for patients 
undergoing SPECT/CT must be refined so as to optimise its utilisation in nuclear 
medicine departments. Therefore its use in patients with equivocal planar lesions should 
be restricted to those patients in whom, 
a.  the correct classification of the lesion(s) in question is expected to alter 
the management of the patient (e.g. in a patient with multiple unequivocal 
metastatic skeletal lesions, the correct classification of additional lesions 
may not affect management of the patient), and 
b. where equivocal lesions exist outside of the lumbar spine on planar 
scintigraphy, SPECT/CT is suggested for lumbar lesions only if SPECT 
facilities are available. 
3. Because there is equal benefit in the use of SPECT/CT in patients with and without 
bone pain, there is no basis for the use of this criterion in deciding whether or not to use 
SPECT/CT on a particular patient. 
4. SPECT/CT images should be interpreted with the aid of a diagnostic radiologist, with 
careful inspection of CT images in order to get the best possible result from a patient 
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study. Alternatively, Nuclear Medicine physicians need to acquire sufficient experience 
with this aspect of CT interpretation. A wide variety a SPECT/CT systems are 
commercially available, ranging from those with low dose CT systems intended only for 
attenuation correction and localisation to full dose multislice diagnostic CT. This work 
was performed using a low dose CT system intended only for attenuation correction and 
localisation. Despite this limitation, the CT study had a marked impact on the 
interpretation of bony lesions. It can be expected that the impact of a technically 
superior CT will be greater. In this situation radiological expertise is likely to be more 
necessary however. 
5. At this stage there is no evidence to suggest that these recommendations should be 
applied differently for different malignancies. 
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